1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Incidence of Arrhythmias and Their Prognostic Value in Patients With Multiple Myeloma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Arrhythmias are common cardiovascular complications in multiple myeloma (MM) patients and are related to a poor prognosis.

          Objective: This study aimed to assess the burden of arrhythmias and their prognostic value in patients with MM.

          Methods: This was a retrospective study of patients with MM between January 2015 and April 2020 at the First Affiliated Hospital of Xi'an Jiaotong University. The incidence of arrhythmia and associated risk factors were evaluated. The relationship between the type of arrhythmia and survival was analyzed.

          Results: A total of 319 patients with MM were identified, and 48.0% (153/319) had arrhythmias. The most common type of arrhythmia was sinus tachycardia (ST) (15.0%, 48/319), followed by sinus bradycardia (SB) (14.4%, 46/319), premature atrial contractions (PACs) (6.3%, 20/319), conduction disorders (CDs) (6.0%, 19/319), atrial fibrillation (AF) (6.0%, 19/319), premature ventricular contractions (PVCs) (4.4%, 14/319) and paroxysmal supraventricular tachycardia (PSVT) (0.6%, 2/319). The patients with arrhythmias had higher levels of log NT-proBNP and creatinine, greater bortezomib use, and a higher incidence of diabetes than those without arrhythmias ( P < 0.05). The all-cause mortality rates of patients without arrhythmias and those with AF, ST, PACs, CDs, SB, and PVCs were 50.6% (84/166), 73.7% (14/19), 60.4% (29/48), 60.0% (12/20), 52.6% (10/19), 34.8% (16/46), and 28.6% (4/14), respectively. In a subgroup analysis of patients experiencing different types of arrhythmias, patients with SB had lower all-cause mortality than patients with AF ( P < 0.01). Univariate and multivariate Cox analyses showed that there was a positive statistically significant association between SB and survival (HR: 0.592 [0.352–0.998], P = 0.049) in a subgroup analysis of different arrhythmias.

          Conclusions: Patients with MM had a heavy arrhythmia burden, and in this study, approximately half of MM patients had arrhythmias. MM patients with SB were associated with lower all-cause mortality than those with AF. SB might be an independent positive factor for prognosis.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: not found
          • Article: not found

          Multiple Myeloma

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

            Three types of anthracycline-induced cardiotoxicities are currently recognized: acute, early-onset chronic, and late-onset chronic. However, data supporting this classification are lacking. We prospectively evaluated incidence, time of occurrence, clinical correlates, and response to heart failure therapy of cardiotoxicity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              International staging system for multiple myeloma.

              There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification. Clinical and laboratory data were gathered on 10,750 previously untreated symptomatic myeloma patients from 17 institutions, including sites in North America, Europe, and Asia. Potential prognostic factors were evaluated by univariate and multivariate techniques. Three modeling approaches were then explored to develop a staging system including two nontree and one tree survival assessment methodologies. Serum beta2-microglobulin (Sbeta2M), serum albumin, platelet count, serum creatinine, and age emerged as powerful predictors of survival and were then used in the tree analysis approach. A combination of Sbeta2M and serum albumin provided the simplest, most powerful and reproducible three-stage classification. This new International Staging System (ISS) was validated in the remaining patients and consists of the following stages: stage I, Sbeta2M less than 3.5 mg/L plus serum albumin > or = 3.5 g/dL (median survival, 62 months); stage II, neither stage I nor III (median survival, 44 months); and stage III, Sbeta2M > or = 5.5 mg/L (median survival, 29 months). The ISS system was further validated by demonstrating effectiveness in patients in North America, Europe, and Asia; in patients less than and > or = 65 years of age; in patients with standard therapy or autotransplantation; and in comparison with the Durie/Salmon staging system. CONCLUSION) The new ISS is simple, based on easy to use variables (Sbeta2M and serum albumin), and recommended for early adoption and widespread use.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Cardiovasc Med
                Front Cardiovasc Med
                Front. Cardiovasc. Med.
                Frontiers in Cardiovascular Medicine
                Frontiers Media S.A.
                2297-055X
                15 November 2021
                2021
                : 8
                : 753918
                Affiliations
                [1] 1Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China
                [2] 2Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China
                [3] 3Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China
                [4] 4Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China
                [5] 5Biobank, The First Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China
                Author notes

                Edited by: Tong Liu, Tianjin Medical University, China

                Reviewed by: Junco S. Warren, Virginia Tech Carilion, United States; Erpeng Liang, Fuwai Central China Cardiovascular Hospital, China

                *Correspondence: Jie Wang wj-8871@ 123456163.com

                This article was submitted to Cardiac Rhythmology, a section of the journal Frontiers in Cardiovascular Medicine

                †These authors have contributed equally to this work and share first authorship

                Article
                10.3389/fcvm.2021.753918
                8634844
                34869663
                0b45ccf8-4c2a-4d7a-901c-daa3ff68c565
                Copyright © 2021 Li, Tang, Zhong, Wei, Song, Liu, Sun and Wang.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 05 August 2021
                : 13 October 2021
                Page count
                Figures: 2, Tables: 3, Equations: 0, References: 44, Pages: 9, Words: 5883
                Categories
                Cardiovascular Medicine
                Original Research

                risk stratification,arrhythmias,multiple myeloma,prognosis,cardiovascular complication

                Comments

                Comment on this article